Table 1.
Incidence of neoplasms in male and female B6C3F1 mice administered 0, 0.0875, 0.175, 0.35, or 0.70 mM glycidamide in the drinking water for two yearsa.
| Neoplasm | Sex | Glycidamide (mM) | ||||
|---|---|---|---|---|---|---|
| 0 | 0.0875 | 0.175 | 0.35 | 0.70 | ||
| Harderian gland adenoma |
Male | 3/47 (6%)*** | 17/47 (36%)*** | 23/47 (49%)*** | 32/46 (70%)*** | 42/47 (89%)*** |
| Female | 2/45 (4%)*** | 19/47 (40%)*** | 20/47 (43%)*** | 24/46 (52%)*** | 40/46 (87%)*** | |
| Lung alveolar/bronchiolar adenoma |
Male | 0/47 (0%)*** | 7/46 (15%)** | 7/47 (15%)** | 13/47 (28%)*** | 17/47 (36%)*** |
| Female | 3/46 (7%)** | 5/48 (10%) | 3/47 (6%) | 7/47 (15%) | 9/44 (20%)** | |
| Stomach (forestomach) squamous cell papilloma |
Male | 0/47 (0%)*** | 2/45 (4%) | 3/48 (6%) | 2/45 (4%) | 10/41 (24%)*** |
| Female | 1/45 (2%)*** | 1/45 (2%) | 1/47 (2%) | 5/45 (11%) | 9/44 (20%)*** | |
| Skin squamous cell papilloma |
Male | 0/47 (0%)*** | 1/48 (2%) | 2/47 (4%) | 1/47 (2%) | 8/46 (17%)*** |
| Skin fibrosarcoma | Female | 0/45 (0%)*** | 1/48 (2%) | 2/47 (4%) | 2/47 (4%) | 9/45 (20%)*** |
| Skin fibrosarcoma or sarcoma |
Female | 0/45 (0%)*** | 1/48 (2%) | 3/47 (6%) | 5/47 (11%)** | 12/45 (27%)*** |
| Mammary gland adenoacanthoma |
Female | 0/45 (0%)*** | 0/48 (0%) | 0/47 (0%) | 1/47 (2%) | 8/45 (18%)*** |
| Mammary gland adenocarcinoma |
Female | 1/45 (2%)*** | 1/48 (2%) | 2/47 (4%) | 9/47 (19%)** | 11/45 (24%)*** |
| Mammary gland adenoacanthoma or adenocarcinoma |
Female | 1/45 (2%)*** | 1/48 (2%) | 2/47 (4%) | 9/47 (19%)** | 18/45 (40%)*** |
| Ovary benign granulosa cell tumor |
Female | 0/45 (0%)* | 0/47 (0%) | 0/47 (0%) | 1/46 (2%) | 2/44 (5%) |
| Ovary malignant granulosa cell tumor |
Female | 0/45 (0%)* | 0/47 (0%) | 0/47 (0%) | 2/46 (4%) | 1/44 (2%) |
| Ovary benign or malignant granulosa cell tumor |
Female | 0/45 (0%)*** | 0/47 (0%) | 0/47 (0%) | 3/46 (7%) | 3/44 (7%) |
The data are reported as the number of animals with a neoplasm per number of animals examined microscopically and (in parentheses) the % incidence. Statistical analyses for dose-related trends and differences in incidence were conducted by survival-adjusted Poly-3 tests.
An asterisk (*) associated with the 0 mM glycidamide incidence indicates a significant (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) dose-related trend with respect to glycidamide. An asterisk (*) associated with a specific treatment indicates a significant (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) difference compared to the 0 mM glycidamide incidence.